News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Wendy Verret

Articles by Wendy Verret

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

BySara M. Tolaney, MD, MPH,Aditya Bardia, MD, MPH,Frederik Marmé,Javier Cortés, MD,Peter Schmid, MD,Delphine Loirat,Olivier Trédan,Eva Ciruelos,Florence Dalenc,Patricia Gómez Pardo,Komal L. Jhaveri,Rosemary Delaney,Theresa Valdez,Oh Kyu Yoon,Hao Wang,Wendy Verret,Hope S. Rugo, MD

August 8th 2024

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH,Frederik Marmé,Javier Cortes,Peter Schmid, MD,Delphine Loirat,Olivier Trédan,Eva Ciruelos,Florence Dalenc,Patricia Gómez Pardo,Komal L. Jhaveri,Rosemary Delaney,Theresa Valdez,Hao Wang,Wendy Verret,Sara M. Tolaney, MD, MPH

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

© 2025 MJH Life Sciences^®

All rights reserved.